Lee's Pharmaceutical Holdings Limited (0950.HK)
0950.HK Stock Price Chart
Explore Lee's Pharmaceutical Holdings Limited interactive price chart. Choose custom timeframes to analyze 0950.HK price movements and trends.
0950.HK Company Profile
Discover essential business fundamentals and corporate details for Lee's Pharmaceutical Holdings Limited (0950.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
15 Jul 2002
Employees
1.02K
Website
https://www.leespharm.comCEO
Siu Fong Lee
Description
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
0950.HK Financial Timeline
Browse a chronological timeline of Lee's Pharmaceutical Holdings Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Mar 2026
Upcoming earnings on 25 Mar 2026
Dividend declared on 12 Sept 2025
A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend will be paid on 3 Oct 2025.
Earnings released on 26 Aug 2025
EPS came in at $0.11 , while revenue for the quarter reached $694.82M .
Dividend declared on 28 May 2025
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 16 Jun 2025.
Earnings released on 22 May 2025
Earnings released on 27 Mar 2025
EPS came in at $0.03 , while revenue for the quarter reached $370.81M .
Earnings released on 24 Mar 2025
EPS came in at $0.03 , while revenue for the quarter reached $370.81M .
Dividend declared on 12 Sept 2024
A dividend of $0.02 per share was announced, adjusted to $0.02. The dividend was paid on 3 Oct 2024.
Earnings released on 28 Aug 2024
EPS came in at $0.05 , while revenue for the quarter reached $329.17M .
Dividend declared on 28 May 2024
A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 17 Jun 2024.
Earnings released on 22 May 2024
EPS came in at $0.05 , while revenue for the quarter reached $329.17M .
Earnings released on 26 Mar 2024
EPS came in at $0.00 , while revenue for the quarter reached $270.36M , missing expectations by -78.84%.
Earnings released on 15 Nov 2023
EPS came in at $0.00 , while revenue for the quarter reached $270.36M .
Dividend declared on 12 Sept 2023
A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 4 Oct 2023.
Earnings released on 30 Aug 2023
EPS came in at $0.01 , while revenue for the quarter reached $256.15M .
Earnings released on 23 Jun 2023
EPS came in at $0.01 , while revenue for the quarter reached $256.15M , missing expectations by -78.16%.
Dividend declared on 25 May 2023
A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 15 Jun 2023.
Earnings released on 30 Mar 2023
EPS came in at -$0.02 , while revenue for the quarter reached $196.97M .
Earnings released on 29 Mar 2023
EPS came in at $0.06 , while revenue for the quarter reached $387.02M .
Dividend declared on 8 Sept 2022
A dividend of $0.01 per share was announced, adjusted to $0.01. The dividend was paid on 27 Sept 2022.
Earnings released on 30 Jun 2022
EPS came in at $0.01 , while revenue for the quarter reached $324.42M .
Dividend declared on 26 May 2022
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 15 Jun 2022.
Earnings released on 25 May 2022
EPS came in at $0.03 , while revenue for the quarter reached $324.75M .
Earnings released on 28 Mar 2022
EPS came in at -$0.31 , while revenue for the quarter reached $313.77M .
Earnings released on 25 Nov 2021
EPS came in at $0.02 , while revenue for the quarter reached $368.34M .
Dividend declared on 15 Sept 2021
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 6 Oct 2021.
Earnings released on 30 Jun 2021
EPS came in at $3.59 , while revenue for the quarter reached $300.91M .
Dividend declared on 31 May 2021
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 18 Jun 2021.
Earnings released on 31 Mar 2021
EPS came in at $0.07 , while revenue for the quarter reached $283.14M .
Earnings released on 31 Dec 2020
EPS came in at $0.01 , while revenue for the quarter reached $322.67M .
Earnings released on 30 Sept 2020
EPS came in at $0.04 , while revenue for the quarter reached $337.33M .
Dividend declared on 14 Sept 2020
A dividend of $0.03 per share was announced, adjusted to $0.03. The dividend was paid on 30 Sept 2020.
0950.HK Stock Performance
Access detailed 0950.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.